AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Accreditation Statement 
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 24.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s) for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, Dec. 11, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 24.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives
Molecularly targeted therapies have achieved great success from the “early days” of selective estrogen receptor modulators and aromatase inhibitors to more recent developments in signal transduction, histone deacetylases, and proteasome inhibitors. However, for each of these success stories, new challenges arise in terms of resistance, further refinement of these “targeted therapies” based on molecular sub-classification, and the opportunity to develop new combination therapies, especially with new immunotherapies.  

Targeted cancer therapeutics allow practicing clinicians to tailor cancer treatment, especially when a target is present in some but not all tumors of a particular type. Some researchers are focusing efforts on the unique set of molecular targets produced by the patient’s tumor, regardless of disease site. Targeted cancer therapies also hold the promise of being more selective for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects, and improving quality of life.

The 2019 program will encompass basic and translational cancer research advances that have direct clinical implications for patients and the clinicians delivering care. Research on antibody drug conjugates, combination therapies, directed T-cell therapy, drug resistance, liquid biopsies for targeted therapeutics, and targeting molecular subtypes of disease sites will be featured topics during the conference. Attendees at this program will be presented with the latest research in the areas of cancer evolution, DNA damage and repair, epigenetics, immunotherapy, liquid biopsies, resistance, and the tumor heterogeneity.

After participating in this CME activity, physicians should be able to: 
  1. Analyze the latest advances in CAR-T therapies and their application beyond current disease sites, both as a monotherapy and in combination with other therapies.
  2. Articulate the role of liquid biopsies in early detection, response monitoring, drug resistance, and early relapse.
  3. Explain the successes and challenges of targeting molecular subtypes.
  4. Identify opportunities for digital health and big data in the preclinical and early clinical trial settings.
  5. Provide examples of rational approaches used to develop combination therapies.
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the meeting app, online planner, or conference website and is available for download.

Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants and will be disclosed at the activity.

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or

Top of page